EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Optogenetic therapeutic strategies for diabetes mellitus

Xin Deng, Dandan Peng, Yuanfa Yao, Ke Huang, Jinling Wang, Zhihao Ma, Junfen Fu, Yingke Xu iD

Journal of Diabetes · 2024-06 · 16 (6)

DOI: 10.1111/1753-0407.13557 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Diabetes, online erschienen am 16.05.2024. Verfasst von Xin Deng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Children's Hospital of Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangz…. Hauptthemen laut MEDLINE: Optogenetics, Diabetes Mellitus. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetes mellitus (DM) is a common chronic disease affecting humans globally. It is characterized by abnormally elevated blood glucose levels due to the failure of insulin production or reduction of insulin sensitivity and functionality. Insulin and glucagon‐like peptide (GLP)‐1 replenishment or improvement of insulin resistance are the two major strategies to treat diabetes. Recently, optogenetics that uses genetically encoded light‐sensitive proteins to precisely control cell functions has been regarded as a novel therapeutic strategy for diabetes. Here, we summarize the latest development of optogenetics and its integration with synthetic biology approaches to produce light‐responsive cells for insulin/GLP‐1 production, amelioration of insulin resistance and neuromodulation of insulin secretion. In addition, we introduce the development of cell encapsulation and delivery methods and smart bioelectronic devices for the in vivo application of optogenetics‐based cell therapy in diabetes. The remaining challenges for optogenetics‐based cell therapy in the clinical translational study are also discussed. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OptogeneticsDiabetes MellitusHumansAnimalsInsulinInsulin ResistanceGlucagon-Like Peptide 1Cell- and Tissue-Based TherapyInsulin-Secreting Cells

Stichwörter der Autor:innen

Optogeneticscell therapydiabetes mellitusinsulininsulin resistance

Substanzen

InsulinGlucagon-Like Peptide 1

Autor:innen und Institutionen

  • Department of Endocrinology, Children's Hospital of Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China.
  • Department of Biomedical Engineering, MOE Key Laboratory of Biomedical Engineering, Zhejiang Provincial Key Laboratory of Cardio-Cerebral Vascular Detection Technology and Medicinal Effectiveness Appraisal, Zhejiang Pro…
  • Binjiang Institute of Zhejiang University, Hangzhou, China.

ORCID-Profile: Yingke Xu

Förderung

  • National Key Research and Development Program of China

Zitieren

APA

Deng, X., Peng, D., Yao, Y., Huang, K., Wang, J., Ma, Z., Fu, J., & Xu, Y. (2024). Optogenetic therapeutic strategies for diabetes mellitus. Journal of Diabetes, 16(6). https://doi.org/10.1111/1753-0407.13557

Vancouver

Deng X, Peng D, Yao Y, Huang K, Wang J, Ma Z, et al. Optogenetic therapeutic strategies for diabetes mellitus. Journal of Diabetes. 2024;16(6). doi:10.1111/1753-0407.13557

BibTeX
@article{Deng2024,
  author = {Deng, Xin and Peng, Dandan and Yao, Yuanfa and Huang, Ke and Wang, Jinling and Ma, Zhihao and Fu, Junfen and Xu, Yingke},
  title = {Optogenetic therapeutic strategies for diabetes mellitus},
  journal = {Journal of Diabetes},
  year = {2024},
  volume = {16},
  number = {6},
  doi = {10.1111/1753-0407.13557}
}
Kostenlos starten →